Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report details a specific share repurchase transaction executed on February 20, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 565,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,420.0 pence per share; lowest price paid was 1,405.5 pence per share.
- Treasury Holdings (Settled): 503,772,927 shares (9.07% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,252,927 shares (10.00% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,050,684,220 shares.
Material Changes
The primary material change reported is the increase in the Company's treasury share holdings following the purchase of 565,000 shares. This transaction increased the proportion of shares held in Treasury to 10.00% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (503,772,927 settled vs. 505,252,927 including unsettled).
- Confirm the denominator for voting rights calculations is 5,050,684,220 shares.
- Check the price range paid for the repurchased shares (1,405.5 to 1,420.0 pence).
- Review the impact of the 10.00% treasury holding on total voting rights.